AbbVie Inc (ABBV)vsViemed Healthcare Inc (VMD)
ABBV
AbbVie Inc
$286.40
-0.14%
HEALTHCARE · Cap: $504.37B
VMD
Viemed Healthcare Inc
$9.99
+3.20%
HEALTHCARE · Cap: $373.26M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 21248% more annual revenue ($64.39B vs $301.61M). ABBV leads profitability with a 9.8% profit margin vs 4.8%. ABBV appears more attractively valued with a PEG of 0.54. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
VMD
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$286.40
$133.43 premium
Margin of Safety
+26.6%
Fair Value
$11.52
Current Price
$9.99
$1.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 23.9% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Smaller company, higher risk/reward
4.8% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : VMD
The strongest argument for VMD centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 23.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : VMD
The primary concerns for VMD are PEG Ratio, P/E Ratio, Market Cap. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while VMD is a growth play — different risk/reward profiles.
VMD carries more volatility with a beta of 1.04 — expect wider price swings.
VMD is growing revenue faster at 23.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 52/100) and 10.2% revenue growth. VMD offers better value entry with a 26.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Viemed Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?